Bronchial intraepithelial recurrence of a pulmonary large cell neuroendocrine carcinoma

Hideaki Kojima a, b, *, Mitsuhiro Isaka a, Kazuhito Funai b, Yasuhisa Ohde a

a Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
b First Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan

A R T I C L E   I N F O

Article history:
Received 20 December 2019
Accepted 27 January 2020
Available online 6 February 2020

Keywords:
Case report
Large cell neuroendocrine carcinoma
High-grade neuroendocrine carcinoma
Recurrence
Bronchial intraepithelial spread
Bronchial intraepithelial recurrence

A B S T R A C T

INTRODUCTION: We encountered a case of a large cell neuroendocrine carcinoma with bronchial intraepithelial spread, a unique form of recurrence.
PRESENTATION OF CASE: A 63-year-old man underwent middle lobectomy and systematic lymph node dissection for lung cancer. The pathological diagnosis was a large cell neuroendocrine carcinoma, and the pathological stage of the tumor was T2aN0M0, stage IB. At 30 months after surgery, the patient complained of continuous cough, and computed tomography revealed a thickened right upper bronchus. Transbronchial biopsy revealed a large cell neuroendocrine carcinoma with bronchial intraepithelial recurrence. The patient died of disease 24 months after recurrence was diagnosed.
DISCUSSION: In cases of centrally located small cell lung carcinoma, it is well known that tumor cells progress along the sub-bronchial mucosa. In contrast, the mechanism of tumor progression of large cell neuroendocrine carcinoma is not fully elucidated because of the rarity of such cases. Endobronchial metastases usually show the presence of polypoid lesions. To the best of our knowledge, this is the first case of endobronchial metastasis from a pulmonary large cell neuroendocrine carcinoma showing bronchial intraepithelial recurrence.
CONCLUSIONS: Clinicians should be aware of this unique form of recurrence in patients with large cell neuroendocrine carcinoma of the lungs.

© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Large cell neuroendocrine carcinoma (LCNEC) of the lungs was first proposed by Travis et al. in 1991 [1], and classified as high-grade neuroendocrine carcinoma (HGNEC) according to the World Health Organization International Histological Classification of Tumours [2]. Among cases treated with surgery, LCNEC accounts for approximately 3% of cases [3]. Because of its rarity, the clinicopathological features of LCNEC are unclear. In particular, the mechanism of tumor progression of LCNEC is still unknown. Herein, we describe a case of LCNEC with bronchial intraepithelial spread, a unique form of recurrence, and this work has been reported in line with the SCARE criteria [4].

2. Presentation of case

A 63-year-old man was referred to our hospital with an abnormal shadow on a screening chest radiograph. He had smoked 2 packs of cigarettes daily for 40 years. Routine laboratory findings and the serum levels of tumor markers were within normal limits. Chest computed tomography revealed a 3.6-cm, well defined, lobulated, solid mass in the right peripheral S5 segment (Fig. 1A). On positron emission tomography, the mass showed 18F-fluorodeoxyglucose accumulation with a maximum standardized uptake value of 14.0 (Fig. 1B). The mass was identified as a non-small cell lung carcinoma on transbronchial lung biopsy and diagnosed as cT2aN0M0, stage IB. Accordingly, we performed right middle lobectomy and systematic lymph node dissection. The resected tumor was 4.0 × 2.5 × 2.0 cm with distinct margins. On microscopic examination, the tumor consisted of large cells with large round nuclei, distinct nucleoli, and scant cytoplasm, with many rosette-like structures (Fig. 2A). Immunohistochemical analyses showed that the tumor was diffusely positive for CD56 (Fig. 2B), and negative for chromogranin and synaptophysin. The final pathological diagnosis was LCNEC, and the pathological stage of the tumor was T2aN0M0, stage IB. In addition, the bronchial epithelium around the primary tumor was exten-

Abbreviations: LCNEC, large cell neuroendocrine carcinoma; HGNEC, high-grade neuroendocrine carcinoma; SCLC, small cell lung carcinoma.

* Corresponding author at: Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
E-mail address: h.kojima@scchr.jp (H. Kojima).

https://doi.org/10.1016/j.ijscr.2020.01.058
2210-2612/© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Radiographic findings of the tumor.
A, Chest computed tomography revealed a 3.6-cm mass in the right peripheral S5 segment.
B, On positron emission tomography, the mass showed 18F-fluorodeoxyglucose accumulation with a maximum standardized uptake value of 14.0.

Fig. 2. Pathological findings of the tumor.
A, The tumor consisted of large cells with large round nuclei, distinct nucleoli, and scant cytoplasm, with many rosette-like structures.
B, The tumor was diffusely positive for CD56.
C, The bronchial epithelium around the primary tumor was extensively invaded by the tumor cells.

3. Discussion
LCNEC and small cell lung carcinoma (SCLC) are classified as HGNEC of the lung according to the World Health Organization International Histological Classification of Tumours [2]. In centrally located SCLC, it is well known that tumor cells progress along the sub-bronchial mucosa. In contrast, the mechanism of tumor progression of LCNEC is not fully elucidated because of its rarity.

We previously reported that the mechanism of tumor progression of peripherally located HGNEC might be bronchial intraepithelial spread but not to the sub-bronchial mucosa and hypothesized that LCNEC cells might have biological characteristics...
of bronchial epithelial cells [5]. In the current case, the bronchial epithelium around the primary tumor was extensively invaded by the tumor cells, which we referred to as “bronchial intraepithelial spread”. We made a diagnosis of LCNEC with bronchial intraepithelial recurrence because the stump of the middle lobe bronchus was intact and this lesion was a skip lesion only in the upper lobe bronchus.

Kiryu et al. reported that endotracheal metastasis is classified into the following 4 types: type I, direct metastasis; type II, bronchial invasion by a parenchymal lesion; type III, bronchial invasion by mediastinal or hilar lymph node metastasis; and type IV, peripheral lesions extending along the proximal bronchus [6]. Endobronchial metastases, in which the bronchial epithelium is directly involved, from primary lung cancer is extremely rare [6,7]. Furthermore, endobronchial metastases usually showed the presence of polypoid lesions. In the current case, transbronchial biopsy revealed LCNEC recurrence as bronchial intraepithelial spread not a polypoid or sub-bronchial mucosal lesion. To our knowledge, this is the first case of endobronchial metastasis from pulmonary LCNEC showing bronchial intraepithelial recurrence.

4. Conclusion

Clinicians should recognize this unique way of tumor progression as bronchial intraepithelial recurrence from pulmonary LCNEC.

**Ethical approval**

This study was approved by the Shizuoka Cancer Center Institutional Review Board (29-J18-30-1-3).

**Consent**

Written informed consent was obtained from the patient’s family for publication of this case presentation and accompanying images.

**Author contribution**

HK designed the study, conducted the investigation, and wrote the manuscript. MI, KF, and YO supervised the work.

**Registration of research studies**

This case report is not research study, therefore approval was not given.

**Guarantor**

Hideaki Kojima accepts full responsibility for the work.

**Provenance and peer review**

Not commissioned, externally peer-reviewed.
Declaration of Competing Interest

The authors declare that they have no competing interests.

References

[1] W.D. Travis, R.I. Linnoila, M.G. Tsokos, C.L. Hitchcock, G.B. Cutler Jr., L. Niemal, et al., Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases, Am. J. Surg. Pathol. 15 (1991) 529–553.

[2] W.D. Travis, E. Brambilla, A.P. Burke, A. Marx, A.G. Nicholson, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th edition, IARC, Lyon, 2015.

[3] C. Roesel, S. Teijung, G. Weinreich, T. Gauler, D. Theegarten, G. Stamatis, et al., A single-institution analysis of the surgical management of pulmonary large cell neuroendocrine carcinomas, Ann. Thorac. Surg. 101 (2016) 1909–1914.

[4] R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A. Fowler, D.P. Orgill, For the SCARE Group, The SCARE 2018 statement: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. (60) (2018) 132–136.

[5] H. Kojima, R. Watanabe, M. Isaka, R. Shimizu, H. Kayata, N. Miyata, et al., High-grade neuroendocrine carcinoma with bronchial intrapithelial tumor spread: possibly a new histologic feature of large-cell neuroendocrine carcinoma, J. Thorac. Oncol. 10 (2015) 1337–1340.

[6] T. Kiyu, H. Hoshi, E. Matsui, H. Iwata, M. Koksbo, K. Shimokawa, et al., Endotracheal/bronchial metastases: clinicopathologic study with special reference to developmental nodes, Chest 119 (2001) 768–775.

[7] M. Yokoba, Y. Nishii, S. Hagiri, S. Tanimura, K. Honma, Endobronchial metastasis from slow-growing lung cancer: a rare case report and review of the literature, Respir. Med. CME 1 (2008) 107–110.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.